Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Freeport-McMoRan Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Freeport-McMoRan Inc trades at $57.5 (market cap $85.29B). The key difference: Freeport-McMoRan Inc is far larger — about 19× ACADIA Pharmaceuticals Inc.'s market cap, and Freeport-McMoRan Inc pays a 1.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FCX | |
|---|---|---|
Market Cap | $4.49B | $85.29B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $71.73 |
52-Week Low | $20.06 | $35.34 |
Enterprise Value | $3.69B | $91.95B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FCX trades at $59.27, down 2.77% on the day, with a bearish technical signal but strong fundamentals including a 10.34% net income margin and consistent earnings beats. Recent news highlights copper demand growth from AI and energy transitions, positioning FCX as a key player. Cash flow trends show improving operational performance, though net cash flow remains negative due to heavy investments.
Outlook is positive with a consensus price target of $71.81, implying 21% upside, supported by robust copper demand and expansion projects. Risks include commodity price volatility and execution challenges. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor debt levels and global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
